Inclusion Criteria:
  -  Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)
  -  The decision to initiate treatment with commercially available NovoMix速 30 has been made by the patient and the treating physician before and independently from the decision to include the patient in this study
  -  Male or female, greater than or equal to 19 years at the time of signing informed consent
  -  Diagnosed with type 2 diabetes and treated with basal insulin plus 1-3 bolus insulin injections per day for at least 24 weeks prior to informed consent
  -  Available and documented HbA1c value less than or equal to 12 weeks prior to initiation of NovoMix速 30 treatment
Exclusion Criteria:
  -  Previous participation in this study. Participation is defined as having given informed consent in this study
  -  Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
  -  Participation in any clinical trial of an approved or non- approved investigational medicinal product within 24 weeks prior to initiation of NovoMix速 30 treatment. Clinical trials do not include non-interventional studies
  -  Hypersensitivity to NovoMix速 30 or to any of the excipients
  -  Pregnancy or intention of becoming pregnant